These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23383195)

  • 1. Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.
    Shionome Y; Yan L; Liu S; Saeki T; Ouchi T
    PLoS One; 2013; 8(1):e55457. PubMed ID: 23383195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
    Payton M; Bush TL; Chung G; Ziegler B; Eden P; McElroy P; Ross S; Cee VJ; Deak HL; Hodous BL; Nguyen HN; Olivieri PR; Romero K; Schenkel LB; Bak A; Stanton M; Dussault I; Patel VF; Geuns-Meyer S; Radinsky R; Kendall RL
    Cancer Res; 2010 Dec; 70(23):9846-54. PubMed ID: 20935223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aurora kinases as targets in drug-resistant neuroblastoma cells.
    Michaelis M; Selt F; Rothweiler F; Löschmann N; Nüsse B; Dirks WG; Zehner R; Cinatl J
    PLoS One; 2014; 9(9):e108758. PubMed ID: 25268132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells.
    Sun J; Knickelbein K; He K; Chen D; Dudgeon C; Shu Y; Yu J; Zhang L
    Mol Cancer Ther; 2014 May; 13(5):1298-308. PubMed ID: 24563542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
    Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
    Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.
    Nair JS; Ho AL; Schwartz GK
    Cell Cycle; 2012 Feb; 11(4):807-17. PubMed ID: 22293494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment.
    Shionome Y; Lin WH; Shiao HY; Hsieh HP; Hsu JT; Ouchi T
    Int J Biol Sci; 2013; 9(4):403-11. PubMed ID: 23678290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells.
    Cheung CH; Lin WH; Hsu JT; Hour TC; Yeh TK; Ko S; Lien TW; Coumar MS; Liu JF; Lai WY; Shiao HY; Lee TR; Hsieh HP; Chang JY
    PLoS One; 2011; 6(8):e23485. PubMed ID: 21887256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
    Ponnurangam S; Standing D; Rangarajan P; Subramaniam D
    Mol Cancer Ther; 2013 May; 12(5):598-609. PubMed ID: 23427297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
    Chowdhury A; Chowdhury S; Tsai MY
    Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S; Costa B; Zappelli E; Da Pozzo E; Sestito S; Nesi G; Campiglia P; Marinelli L; Novellino E; Rapposelli S; Martini C
    Sci Rep; 2015 Apr; 5():9956. PubMed ID: 25898313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.
    Liu Q; Xu C; Kirubakaran S; Zhang X; Hur W; Liu Y; Kwiatkowski NP; Wang J; Westover KD; Gao P; Ercan D; Niepel M; Thoreen CC; Kang SA; Patricelli MP; Wang Y; Tupper T; Altabef A; Kawamura H; Held KD; Chou DM; Elledge SJ; Janne PA; Wong KK; Sabatini DM; Gray NS
    Cancer Res; 2013 Apr; 73(8):2574-86. PubMed ID: 23436801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
    Kojima K; Konopleva M; Tsao T; Nakakuma H; Andreeff M
    Blood; 2008 Oct; 112(7):2886-95. PubMed ID: 18633130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of nutlin-3 and VX-680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53.
    Cheok CF; Kua N; Kaldis P; Lane DP
    Cell Death Differ; 2010 Sep; 17(9):1486-500. PubMed ID: 20203688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
    Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
    Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.